Shots:

• UCB to receive $120M and is eligible to receive $2B as cost reimbursement- development- and commercial milestones as well as royalties on sales of the therapies- if Roche proceeds the clinical development. Roche to get an exclusive license to develop and commercialize UCB0107 for AD
• UCB to fund and perform a POC study in AD and- upon the availability of the results of that study while Roche has the right to progress with the development or return full rights back to UCB
• UCB0107 is an IgG4 mAb targeting a central Tau epitope- being developed to block/reduce the spread of Tau pathology. UCB continues to develop UCB0107 in PSP- with anticipated initiation of P-III study in Q2’21

­ Ref: PRNewswire | Image: Roche